Education
About Us
Working with TipRanks
Follow Us
Staar Surgical (STAA)
NASDAQ:STAA
STAA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.50 - $38.60
Previous CloseN/A
Volume326.32K
Average Volume (3M)2.50M
Market Cap
$1.36B
Enterprise Value$688.52M
Total Cash (Recent Filing)$189.88M
Total Debt (Recent Filing)$40.52M
Price to Earnings (P/E)55.8
Beta0.88
Next Earnings
Oct 29, 2025EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding49,553,036
10 Day Avg. Volume804,678
30 Day Avg. Volume2,500,639
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue3.07
Enterprise Value/Gross Profit4.28
Enterprise Value/Ebitda-9.40
Forecast
1Y Price Target
$24.86Price Target Upside-9.14% Downside
Rating ConsensusHold
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
EarningsSTAA's 2Q25 revenue beat consensus with growth of 10%.
Market RecoveryManagement sounds confident that China can turn around in the second half of 2025, which is its biggest market by far.
Strategic AcquisitionThe acquisition makes sense strategically, and valuation appears attractive for a differentiated technology.
Bears Say
Acquisition ImpactThe deal will be dilutive in the first year and modestly accretive in the second year.
Macroeconomic UncertaintyVisibility into a macroeconomic turnaround is difficult to predict and purchasing patterns for a premium elective procedure may take time to fully recover.
Stock PerformanceThe stock is down 58% in the past year, and there is a need to see proof before getting more constructive on the name.
Staar Surgical News
STAA FAQ
What was Staar Surgical’s price range in the past 12 months?
Staar Surgical lowest stock price was $13.50 and its highest was $38.60 in the past 12 months.
What is Staar Surgical’s market cap?
Staar Surgical’s market cap is $1.36B.
When is Staar Surgical’s upcoming earnings report date?
Staar Surgical’s upcoming earnings report date is Oct 29, 2025 which is in 58 days.
How were Staar Surgical’s earnings last quarter?
Staar Surgical released its earnings results on Aug 06, 2025. The company reported -$0.339 earnings per share for the quarter, beating the consensus estimate of -$0.561 by $0.222.
Is Staar Surgical overvalued?
According to Wall Street analysts Staar Surgical’s price is currently Overvalued.
Does Staar Surgical pay dividends?
Staar Surgical does not currently pay dividends.
What is Staar Surgical’s EPS estimate?
Staar Surgical’s EPS estimate is 0.18.
How many shares outstanding does Staar Surgical have?
Staar Surgical has 49,553,036 shares outstanding.
What happened to Staar Surgical’s price movement after its last earnings report?
Staar Surgical reported an EPS of -$0.339 in its last earnings report, beating expectations of -$0.561. Following the earnings report the stock price went up 0.186%.
Which hedge fund is a major shareholder of Staar Surgical?
Currently, no hedge funds are holding shares in STAA
Staar Surgical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$24.86 (-9.14% Downside)
$24.86 (-9.14% Downside)
Blogger Sentiment
Bullish
STAA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 720.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.87%
12-Months-Change
Fundamentals
Return on Equity
-25.55%
Trailing 12-Months
Asset Growth
-14.62%
Trailing 12-Months
Company Description
Staar Surgical
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
STAA Company Deck
STAA Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Negative
The earnings call reflected significant challenges primarily due to the decline in China sales and impact on profitability, but highlighted strategic initiatives in management restructuring, tariff mitigation, and expansion in global markets. The positive strides in operational efficiency and global sales growth were overshadowed by the severe revenue and profitability declines.View all STAA earnings summariesSTAA Stock 12 Month Forecast
Average Price Target
$24.86
▼(-9.14% Downside)
Technical Analysis
Baxter International
―
Intuitive Surgical
―
Masimo
―
Resmed
―
Bausch + Lomb Corporation
―
Ownership Overview
55.22% Insiders
16.39% Mutual Funds
0.37% Other Institutional Investors
2.21% Public Companies and
Individual Investors